BACKGROUND: Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patient populations. The objective of this study was to assess the safety and tolerability of evolocumab in a pooled safety analysis from phase 2 or 3 randomized and placebo or comparator-controlled trials (integrated parent trials) and the first year of open-label extension (OLE) trials that included a standard-ofcare control group.
L owering low-density lipoprotein cholesterol (LDL-C) is an essential component of the therapeutic paradigm to reducing the morbidity and mortality associated with cardiovascular disease in both primary and secondary prevention settings. According to guidelines published around the world, statins are designated as first-line therapy for treating hypercholesterolemia, specifically in patients with high cardiovascular risk. [1] [2] [3] [4] However, a sizeable number of patients do not achieve riskstratified goal LDL-C levels or percent reductions with statin therapy alone 5, 6 or in combination with ezetimibe. 7 Blocking the interaction of PCSK9 (proprotein convertase subtilisin/kexin type 9) with low-density lipoprotein receptors (LDLRs) has emerged as a highly effective therapeutic strategy for lowering LDL-C. On binding to LDLR, PCSK9 promotes increased lysosomal LDLR degradation, reduced hepatocyte cell surface expression of LDLR, and increased plasma LDL-C concentrations. 8 Evolocumab is a subcutaneously administered fully human monoclonal IgG2 antibody to PCSK9 that is approved for use in the United States and Europe, among other countries. Regulatory approval was based on review of the comprehensive clinical trial program, PRO-FICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 in Different Populations). These trials demonstrated robust reductions of LDL-C with evolocumab treatment in comparison with placebo or ezetimibe across a broad population of patients with hypercholesterolemia, including those with familial hypercholesterolemia or other high-risk conditions, and statin-intolerant patients, as well. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The safety of newly emerging antihypercholesterolemia agents is of paramount importance. Any such agent will be used on a chronic basis and must be both safe and well tolerated to promote optimal adherence. Each of the evolocumab trials showed a favorable safety and tolerability profile of evolocumab in comparison with placebo or control regimens. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] To gain further understanding of the safety profile of evolocumab, as part of the PROFICIO program, we assessed safety and tolerability in a pooled analysis from patients enrolled in the randomized placebo-or ezetimibe-controlled phase 2 and 3 trials and during the year 1 standard-of-care (SoC)-controlled portion of the openlabel extension (OLE) trials.
METHODS Patients
Patients were enrolled in 1 of 12 phase 2 and 3 evolocumab parent clinical trials (Table 1 and Figure) . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] All patients provided written informed consent and the individual protocols were approved by each institutional review board. All patients completing a phase 2 or 3 parent trial on study drug were eligible to enroll in SoC-controlled open-label extension trials.
Data Sources
Each parent trial included was a double-blind, placebo-controlled randomized trial of 12 weeks duration with the exception of 1 trial of 6 weeks duration (THOMAS-1 [Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen]; NCT01849497) and 1 trial of 52 weeks duration (DESCARTES [Durable Effect of PCSK9 Antibody Compared with Placebo Study]). 9 Dosing regimens and frequencies for evolocumab subcutaneous administration in the phase 2 parent trials were as follows: 70, 105, and 140 mg every 2 weeks and 280, 350, and 420 mg monthly . The phase 3 parent trials used evolocumab regimens of 140 mg every 2 weeks and 420 mg monthly. Five trials included an ezetimibe-treated arm, alone or in combination with placebo. 12, 13, [16] [17] [18] A total of 6026 patients were randomly assigned and received at least 1 dose of evolocumab or control in the 12 phase 2 and 3 parent studies. Of these patients, 4465 (74%) enrolled in 2 ongoing open-label extension studies: OSLER-1 (Open-Label Study of Long-Term Evaluation Against LDL-C), which enrolled patients from the phase 2 trials, 19 and OSLER-2, which enrolled patients from the phase 3 trials. The OSLER trials included a SoC-controlled period for the first year of follow-up, followed by a period during which all patients received evolocumab. On enrollment to each OSLER trial, patients were again randomly assigned 2:1 to receive evolocumab plus SoC or SoC alone.
Clinical Perspective
What Is New? What Are the Clinical Implications?
• Evolocumab is approved for reducing serum levels of low-density lipoprotein cholesterol across diverse patient populations.
• The present analysis confirms that longer-term treatment with evolocumab, either alone or in combination with other lipid-lowering therapies, may have a favorable benefit-risk profile.
Adverse event (AE) data were pooled from the 6026 patients in phase 2 and 3 studies (integrated parent studies) and from the 4465 patients after the SoC-controlled 1-year period in the OSLER studies. From these respective data sets, 5942 of 6026 patients and 4417 of 4465 patients had at least 1 postbaseline LDL-C evaluation and were analyzed for safety *At screening, low or atypical dose statin permitted: weekly doses of ≤70 mg atorvastatin; ≤140 mg simvastatin, pravastatin, lovastatin; ≤35 mg rosuvastatin; ≤280 mg fluvastatin.
†Patients randomly assigned to 1 of 5 background statin doses: moderate intensity (atorvastatin 10 mg, simvastatin 40 mg, or rosuvastatin 5 mg daily) or high intensity (atorvastatin 80 mg or rosuvastatin 40 mg daily).
‡Patients assigned background lipid-lowering therapy according to screening LDL-C and NCEP ATP III risk category: diet alone, diet plus atorvastatin 10 mg orally daily, diet plus atorvastatin 80 mg orally daily, or diet plus atorvastatin 80 mg orally daily and ezetimibe 10 mg orally daily. associated with attainment of postbaseline on-treatment very low LDL-C (<25 mg/dL) in a post hoc exploratory analysis. Data were compared between patients who never achieved LDL-C <40 mg/dL and patients who ever achieved LDL-C <40 mg/dL. Patients in the latter category were further divided into subgroups of those who ever achieved LDL-C <25 mg/dL and patients who ever achieved LDL-C ≥25 mg/dL to <40 mg/ dL. Data cutoff dates were October 1, 2014 for OSLER-1 and April 1, 2015 for OSLER-2; all patients from OSLER-1 had completed year 1 by October 2014.
Safety End Points
Safety end points of the trials included the incidence of AEs, serious AEs, AEs of interest, laboratory values, and antievolocumab antibodies. AEs in this integrated analysis were coded by using version 18.0 of the Medical Dictionary for Regulatory Activities. AEs in the individual parent trials were coded by using the most current version of the Medical Dictionary for Regulatory Activities at the time of database lock. AEs were graded according to the Common Terminology Criteria for Adverse Events version 4.0 20 when applicable. The immunogenicity of evolocumab was evaluated using an electrochemiluminescent bridging immunoassay for the detection of binding antidrug antibodies. For patients whose sera tested positive in the immunoassay, an in vitro biological assay was performed to detect neutralizing antibodies.
Statistical Analysis
Safety analyses were conducted using descriptive statistics. Safety data were reported as observed. All analyses were performed with SAS/STAT, version 9.2 (SAS Institute). Patient incidences of AEs were summarized for all AEs, serious AEs, and AEs of interest. AEs were tabulated and reported separately for the parent studies and the OLE studies; an identical AE occurring in a patient in both the parent study and the OLE study was therefore recorded twice and reported separately as occurring in each data set. Incidences of AEs were tabulated by system organ class, preferred term, and grade. Summaries of AEs occurring in at least 2% of the patients by preferred term in any treatment arm in parent or extension studies were provided in descending order of frequency. Descriptive statistics were provided for actual values and changes from baseline of laboratory parameters. Patient incidences of creatine kinase and liver function test abnormalities were summarized. The incidence of patients who developed antievolocumab antibodies at any time was tabulated. The studies were not powered for safety end points; therefore, no inferential statistical analyses with associated P values were conducted.
RESULTS

Baseline Characteristics
The phase 2 and 3 parent evolocumab studies included in this analysis are summarized in Table 1 . Trials included patients with primary hyperlipidemia, familial hypercholesterolemia, and statin intolerance. Comparator therapies included placebo and ezetimibe. Background therapies included no therapy, statin, or statin combined with ezetimibe (ezetimibe was not a comparator in these studies). Baseline characteristics of the integrated safety population are summarized in Table 2 . In the parent trial population, 49.5% of patients were men, 83.4% were white, the mean age of participants was 57.5 years, and 73.5% of patients were randomly assigned to receive evolocumab in combination with a statin. In the extension trial population, 50.5% were men, 85.7% were white, and the mean age of participants was 58.0 years. Of the 6026 patients enrolled in the parent studies, 4465 (74.1%) enrolled in the extension trials. Reasons for not continuing in the extension trials are detailed in online-only Data Supplement Table I . Of the 1561 patients who did not enroll, 5.9% discontinued study drug early because of an AE in the parent trials. Median (range) evolocumab exposure was 2.8 (0-12.3) months in the parent studies and 11.1 (0-13.1) months in the extension studies. Of the 6026 patients enrolled in the parent studies, 4635 patients (76.9%) had ≥12 months of evolocumab exposure and 610 patients (10.1%) had ≥18 months of evolocumab exposure.
Safety Outcomes
Overall AE rates were similar between evolocumab and control in the parent studies (51.1% versus 49.6%, respectively) and in the year 1 SoC-controlled period of the OLE studies (70.0% versus 66.0%, respectively; Table 3 ). The majority of the difference between arms in the OLE studies is related to the occurrence of injection-site reactions (ISRs), which occurred in 4.4% of patients receiving evolocumab and are not reported for patients in the SoC-control arm, because these patients were not receiving injectable therapy. The majority of AEs were mild to moderate in severity in each treatment group. Serious AEs were also comparable between evolocumab and control, occurring in 2.8% and 2.1%, respectively, during the parent studies and in 7.8% and 7.8%, respectively, during the OLE studies. AEs leading to study drug discontinuation in the parent trials occurred in 1.9% of evolocumab-treated patients and 2.3% of control-treated patients; 2.5% of evolocumabtreated patients discontinued drug because of an AE during the year 1 SoC-controlled period of the OLE studies. Fatal AEs occurred in 3 patients (0.08%) in the evolocumab arm and 1 patient (0.05%) in the control arm of the parent trials and in 4 patients (0.13%) in the evolocumab arm and 6 patients (0.40%) in the SoC arm of the OLE trials. Nasopharyngitis was the most common AE among evolocumab-treated patients during both periods (5.9% in the parent studies and 9.4% in the OLE studies; rates in the control-and SoC-treated groups were 4.8% and 9.5%, respectively). ISRs were observed in 3.3% of evolocumab-treated patients and 3.0% of control-treated patients in the parent trials. Among these patients, 95.4% of evolocumab-associated ISRs were mild in severity and 4.6% were of moderate severity. In the OLE trials, 91.6% of evolocumabassociated ISRs were mild in severity and 8.4% were of moderate severity. Hypersensitivity reactions were observed in 3.2% of evolocumab-treated patients and 2.4% of patients in the control arm of parent trials and in 5.7% of evolocumab-treated patients and 4.3% of SoC-treated patients in the OLE trials. In the parent trials, 73.0% of evolocumab-associated hypersensitivity reactions were mild in severity, 26.2% were of moderate severity, and 1 patient (0.8%) experienced a severe reaction, consisting of worsening urticaria. In the OLE trials, the majority of hypersensitivity reactions were of mild to moderate severity.
Muscle-related AEs (Table 4) were similar in overall frequency and type of event in the evolocumab, control, or SoC groups. Neurocognitive-related AEs (Table 5) were similar with evolocumab (0.1%) in comparison with control (0.3%) in the blinded phase 2 and 3 parent trials. In the OLE studies, the rate of neurocognitive events was 0.6%, and consisted primarily of amnesia and memory impairment in both treatment groups. Neurocognitive events were observed in 0.9% of patients receiving evolocumab plus SoC and 0.3% of patients receiving SoC alone. There were small increases in amnesia (0.3% versus 0.1%) and in dementia, confusional state, and mental impairment (0.1% versus 0%). The proportion of patients discontinuing study drug for neurocognitive events *Control includes placebo and ezetimibe treatment groups. †Inability to tolerate ≥1 statin at any dose or an increase in dose above weekly maximums of rosuvastatin, 35 mg; atorvastatin, 70 mg; simvastatin, 140 mg; pravastatin, 140 mg; lovastatin, 140 mg; or fluvastatin, 280 mg, because of intolerable myalgia or myopathy (myalgia plus elevated creatine kinase) and having symptom improvement or resolution with statin discontinuation. 20 ‡Potential ISRs were identified using preferred terms consistent with ISRs from the administration site reactions and ISRs high-level terms. N/A indicates not applicable because these patients were receiving standard of care and therefore not receiving injections.
§Potential hypersensitivity reactions were identified using the hypersensitivity standardized MedDRA query (SMQ).
was <0.1% in each arm of the parent trials and 0.1% of patients receiving evolocumab in the extension study. Laboratory evaluations (Table 6 ) revealed that creatine kinase and liver enzyme elevations were infrequent and similar between groups. No drug-induced liver injury events were assessed to be associated with evolocumab use. No clinically meaningful changes in renal laboratory parameters occurred over 1 year in the extension studies or during the 52-week, randomized DESCARTES parent trial.
No neutralizing antievolocumab antibodies were detected in the parent or OLE studies. The incidences of binding, nonneutralizing antibodies were 0.2% (9 of 3946 evolocumab-treated patients) during the parent studies and 0.4% (11 of 2976 evolocumab-treated patients) during the OLE. During the OLE, a total of 13 positive binding antievolocumab results were observed in the 11 patients. The majority (9 [69.2%]) of the positive results occurred at weeks 12 or 24. One positive result occurred at week 48, in a patient who had prior positive results at weeks 4 and 12, and had received placebo during the parent trials. These data suggest that the development of binding, nonneutralizing antievolocumab antibodies does not increase with longer duration of evolocumab administration up to 48 weeks.
No association between time exposure to evolocumab and AEs was observed (Table 7) . Among the 4 quarters of the OLE, AE rates in evolocumab-treated patients ranged from 40.3% in the first quarter to 29.4% in the last quarter. Serious AE rates ranged from 2.2% in the first quarter to 1.8% in the last quarter.
Mean changes from baseline for systolic and diastolic blood pressure were similar among treatment groups over time. In the integrated parent studies, the mean change from baseline to each study time point in systolic and diastolic blood pressure, respectively, ranged from -1.1 to 0.6 mm Hg (systolic) and -0.8 to 0.2 mm Hg (diastolic) in the any evolocumab group and -1.0 to 1.0 mm Hg (systolic) and -0.8 to 0.1 mm Hg (diastolic) in the any control group. In the year 1 SoC-controlled period, the mean change from baseline to each study time point in systolic and diastolic blood pressure, respectively, ranged from -0.9 to 2.1 mm Hg (systolic) and -1.5 to 0.8 mm Hg (diastolic) in the evolocumab plus SoC group and -0.4 to 2.0 mm Hg (systolic) and 0.2 to 0.9 mm Hg (diastolic) in the SoC alone group.
Safety Outcomes According to Lowest Achieved LDL-C (Nonrandomized Analysis)
Baseline characteristics of patients according to the lowest level of LDL-C achieved (<25 mg/dL, ≥25 mg/dL to <40 mg/dL, <40 mg/dL, or ≥40 mg/dL) are shown in online-only Data Supplement Table II . Analysis of AEs according to these LDL-C subgroups demonstrated no evidence of increased risk associated with very low LDL levels achieved with evolocumab as monotherapy or in addition to background lipid-lowering therapy (online-only Data Supplement Table III ). In the parent trials, AE rates in patients receiving evolocumab who achieved LDL-C of <25 mg/dL or ≥25 mg/dL to <40 mg/dL were 51.4% and 50.4%, respectively. These rates were similar to Muscle-related adverse events are listed in decreasing order of frequency in the evolocumab arm of the parent trials. AE indicates adverse event; and SoC, standard of care.
*Control includes placebo and ezetimibe treatment groups. †System organ class and preferred terms.
evolocumab-treated patients whose lowest LDL-C level was ≥40 mg/dL (52.1%). In the OLE trials, AE rates in patients receiving evolocumab who achieved LDL-C of <25 mg/dL or ≥25 mg/dL to <40 mg/dL were 70.2% and 69.2%, respectively. These rates were also consistent with evolocumab-treated patients whose lowest LDL-C level was ≥40 mg/dL (71.1%). No difference in neurocognitive or muscle-related AEs was observed in patients with progressively lower achieved LDL-C levels in comparison with patients with LDL-C ≥40 mg/ dL. There were no discernible differences in key laboratory assessments with evolocumab in comparison with control or SoC across the lowest LDL-C levels achieved (online-only Data Supplement Table IV) .
DISCUSSION
This pooled safety analysis from the evolocumab PRO-FICIO program demonstrates that the overall rates of AEs were similar in the evolocumab and control groups among >6000 patients in randomized double-blind and OLE studies. Together with the robust LDL-C lowering observed with evolocumab in comparison with control across diverse patient populations in these trials, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] these findings support a positive benefit-risk profile for evolocumab as an addition to the therapeutic armamentarium for LDL-C reduction and form the basis for regulatory approval of evolocumab. The favorable tolerability profile of evolocumab promotes adherence to treatment, and is thus reassuring given the fact that a sizeable number of patients treated with statins alone or in combination with ezetimibe are unable to achieve their risk-stratified goal for LDL-C reduction. 7, 21 The majority of clinical trials in the PROFICIO program were designed to evaluate the addition of evolocumab to statin therapy with or without other lipid-lowering therapies to address this need. Therefore, the tolerability of evolocumab in the setting of polypharmacy in high-risk patients is of paramount importance.
Evolocumab is a monoclonal antibody that binds PCSK9 in the extracellular space and induces steric hindrance so that PCSK9 is no longer able to bind to the LDLR and chaperone the receptor into the lysosome for proteolytic destruction. 8, 22, 23 Because of their size, monoclonal antibodies are unlikely to undergo membrane transport into hepatocytes or other tissues. *Control includes placebo and ezetimibe treatment groups. †Neurocognitive events were identified using deliria (including confusion), cognitive and attention disorders and disturbances, dementia and amnestic conditions, disturbances in thinking and perception, and mental impairment disorders high-level group terms.
Because of their high target specificity and extracellular mechanism of action, monoclonal antibodies, like evolocumab, are unlikely to lead to AEs stemming from drug interactions.
Myopathy, including rhabdomyolysis, is known to occur, albeit rarely, in patients receiving statins. This analysis explored the impact of evolocumab on risk for myositis, muscle fatigue, myalgia, elevation in serum levels of creatine kinase, and other muscle-related AEs. No evidence of increased risk for these events was observed, despite the inclusion of statin-intolerant patients who had experienced prior myalgia on statin treatment.
Whether statin therapy is associated with an increased risk for neurocognitive deficits and dementia has been evaluated and no definitive evidence for the association exists. 24 In both the HPS (Heart Protection Study) and the PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) trials, subgroup analyses using neurocognitive testing failed to reveal any increased risk for neurocognitive disorders with statin therapy in comparison with placebo. 25, 26 In the integrated 12-week evolocumab parent studies, neurocognitive AEs were similar between evolocumab and control groups. In the open-label integrated extension studies, patients in this ALT indicates alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase; SoC, standard of care; and ULN, upper limit of normal.
*Control includes placebo and ezetimibe treatment groups. †Serum creatinine 88.4 μmol/L = 1 mg/dL. ‡For the parent trials, week 52 renal function data are available from the DESCARTES study, which enrolled 901 patients (evolocumab plus background therapy, n=599; placebo plus background therapy, n=302).
§Blood urea nitrogen 0.36 mmol/L = 1 mg/dL.
analysis were treated for up to 1 year, and neurocognitive AEs were numerically higher in the evolocumab plus SoC group (n=27 [0.9%]) relative to the SoC group (n=5 [0.3%]). The proportion of patients discontinuing study drug for neurocognitive events was low. Similar data were observed with alirocumab in the ODYSSEY LONG TERM study (1.2%, alirocumab versus 0.5%, control).
27
Certain limitations should be considered when interpreting these results. First, the numbers of neurocognitive events are small and are largely based on patient selfreporting. Investigators did not perform formal neurocognitive testing, and data specific to neurocognitive events were not systematically collected. Second, the fact that the evolocumab extension studies were open label may have led to responder bias. Third, the length of follow-up is relatively short for identifying neurocognitive deficits. Finally, the population is relatively young (<4% of patients were ≥75 years of age at baseline) with a low rate (<10%) of cerebrovascular disease, suggesting a more favorable baseline neurocognitive status. There is no evidence that either evolocumab or evolocumab-PCSK9 complexes cross the bloodbrain barrier to exert neurotoxicity, 28 and preliminary data from 5777 participants did not support a link of a PCSK9 single-nucleotide polymorphism to cognitive dysfunction in PROSPER. 29 We acknowledge that the neurocognitive safety of antihyperlipidemic agents is an important issue. A more definitive approach to evaluating the impact of evolocumab on neurocognitive function has been undertaken. The EBBINGHAUS trial (Evaluating PCSK9 Binding antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects; NCT02207634) 30 is a dedicated study of cognition that enrolled >1900 patients participating in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; NCT01764633), which in itself has enrolled 27 564 patients. 31 In EBBINGHAUS, patients who were randomly assigned to receive either evolocumab plus high-or moderate-intensity statin or placebo plus high-or moderate-intensity statin were evaluated for prospective changes in neurocognitive function using the Cambridge Neuropsychological Test Automated Battery. This study provides a rigorous evaluation of the effects of evolocumab in combination with a statin on neurocognitive impairment compared with statin therapy alone. Results of EBBINGHAUS were presented at a scientific meeting. The effect of anti-PCSK9 antibodies on cognitive function will also be monitored in ongoing phase 3 studies with other antibodies such as the alirocumab ODYSSEY OUTCOMES study. 32 No evidence emerged that evolocumab is associated with an increased risk for acute renal injury or renal failure, and no impact on blood pressure was observed. No druginduced liver injury events were assessed to be associated with evolocumab use in this analysis. No association between time exposure to evolocumab and AE rates were identified during the OLE. Finally, to date, neutralizing antievolocumab antibodies have not been detected.
A post hoc exploratory analysis according to achieved LDL-C levels revealed no evidence of differences in risk of AEs in patients achieving very low LDL-C levels (<25 mg/dL). This analysis is limited by the postbaseline definition of subgroups according to on-treatment LDL-C rather than randomized groups. As such, imbalances among groups can occur that can confound safety results. Additionally, small numbers of patients per subgroup precludes the ability to perform meaningful comparisons between evolocumab and control.
CONCLUSIONS
The PROFICIO integrated safety analysis of evolocumab included 6026 patients pooled across phase 2 and 3 trials and 4465 patients that continued in open-label extension trials. With median evolocumab exposures of 2.8 months (phase 2 and 3 trials) and 11.1 months (extension studies), the findings support a positive benefit-risk profile for evolocumab. ISRs associated with evolocumab were mild to moderate in severity. Evolocumab therapy was not associated with significant risk for hepatotoxicity, muscle-related AEs, or neurocognitive events.
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